Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

ion of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expectations related to the clinical trials and continued development of abetimus sodium, also known as Riquent. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials, including the ASPEN study; the enrollment rate of such study and the actual rate of renal flares in such study; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission regarding abetimus sodium; La Jolla Pharmaceutical's ability to and success in executing the ASPEN study and its ability to produce sufficient quantities of material for such study; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... ... and supplier, announces the launch of their 2nd generation cell therapy POD® design. ... miniPOD CT, but it also represents a new POD® design. , “G-CON ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
(Date:7/29/2015)... 29, 2015  Therapath Neuropathology ( www.Therapath.com ), ... with VA and Military Medical centers both domestically ... (ENFD) and Sweat Gland Nerve Fiber Density (SGNFD) ... https://therapath.com/skin ). Demonstration of a ... on punch skin biopsy is a highly sensitive ...
(Date:7/29/2015)... 29, 2015  Indivior PLC (LON: INDV) today announced ... spray was accepted and received Priority Review by the ... of opioid overdose. This naloxone nasal spray comes as ... optimal absorption into the nasal mucosa. 1 The ... individuals may be better equipped to help an opioid ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Advantage in Key ... Maturity Zone, ST. LOUIS, ... who used DEKALB(R) corn seed stacked,with YieldGard VT Triple(TM) from Monsanto Company ... and,technologies in 2007., Data from nearly 1,700 on-farm field trials showed ...
... Worldwide Rights for All Potential Uses, Excluding U.S. ... for Celiac Disease BASINGSTOKE, England and PHILADELPHIA, ... TSX: SHQ),the global specialty biopharmaceutical company, today announces ... U.S. and Japan, to AT-1001,from Alba Therapeutics Corporation ...
... INDIANAPOLIS, Dec. 14 Eli Lilly and Company,(NYSE: ... join Lilly in,January, 2008, as a Distinguished Lilly Scholar ... absolutely delighted to have Dr. Conley join our team ... Medical Division. "Rob,is a well-known thought leader, clinician and ...
Cached Biology Technology:Farmers Across the U.S. Realize Double-Digit Yield Advantage From DEKALB(R) Corn Seeds With Triple-Stacked Traits 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 3Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2
(Date:7/8/2015)... , July 8, 2015 The ... as this summer,s must have products such as wearables, smart ... as popularity for biometrics based devices continues to rapidly grow.  ... Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... This release is available in Spanish . , ... for Research in Biomedicine (IRB Barcelona), reveal a surprising new ... to date. Found in the cell membrane, this protein activates ... make the cell divide, grow, migrate, specialise or die. Notch ...
... bacterium found in about 50% of humans worldwide, can cause stomach ... F1000 Medicine Reports , Seiji Shiota and Yoshio Yamaoka discuss ... Infection by the H. pylori bacterium can approach 100% ... many develop problems including stomach ulcers. H. pylori causes ...
... have created a molecular image of a system that moves ... for biology and could provide insights to minimize energy loss ... the country. The research, led by Carrie Wilmot, ... published in the March 12 issue of Science . ...
Cached Biology News:Opposing functions of a key molecule in the development of organisms 2Opposing functions of a key molecule in the development of organisms 3Preventing gastric cancer with antibiotics 2U of Minnesota researcher discovers how electricity moves through cells 2